Medivation Inc (MDVN) 62.10 $MDVN
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.10 (-0.64), BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), GILD: 86.55 (+1.08), UNH: 141.27 (+0.47), MRK: 59.35 (+0.57), ALXN: 124.42 (+1.08), XOM: 93.54 (+0.58), CVX: 104.77 (+1.72), REGN: 378.35 (+6.90), CELG: 105.03 (+0.62)
Blog Coverage Biotech Major Medivation Open to Takeover Talks
ACCESSWIRE - Wed Jul 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / July 6, 2016 / Active Wall St. blog coverage looks at the headline from Medivation Inc. (NASDAQ: MDVN) as the U.S. company signs confidentiality agreements with Paris-based Sanofi S.A. (NYSE: SNY), Pfizer Inc. (NYSE: PFE) and Celgene Corp. (NASDAQ: CELG) among others. Register with us now for your free membership and blog access at:
MDVN: 62.10 (-0.64), PFE: 36.12 (+0.35), ABBV: 64.16 (+0.73), SNY: 40.85 (-0.14), CELG: 105.03 (+0.62)
Medivation Enters into Confidentiality Agreements, Including with Sanofi
BusinessWire - Tue Jul 05, 3:15PM CDT
--Board Committed to Delivering Value and Acting in Stockholders' Best Interests
MDVN: 62.10 (-0.64)
Merger & Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizer's $5.2 Billion Purchase
ACCESSWIRE - Thu Jun 30, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / June 30, 2016 / The Biotech Industry received a boost last month after Pfizer Inc. announced its acquisition of Anacor Pharmaceuticals Inc. and its eczema gel, crisaborole, for $5.2 billion. Under the terms of the deal, Pfizer agreed to pay $99.25 per share in cash for Anacor, which represented a 55 percent premium to Anacor's closing price of $64.03 on May 13th. The transaction has already received approval from both the company's board of directors and is expected to be completed in the third quarter of 2016. The acquisition could potentially kick start merger and acquisition activity within the biotech industry as larger pharmaceutical and biotech companies will also look to boost revenues through acquisitions. Register with us now for your free membership and gain access to our biotech reports at: www.rdinvesting.com. Today we feature reports on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Exelixis, Inc. (NASDAQ: EXEL), Medivation Inc. (NASDAQ: MDVN) and Novavax, Inc. (NASDAQ: NVAX).
MDVN: 62.10 (-0.64), ACAD: 34.62 (+1.11), NVAX: 7.62 (+0.16), PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14), EXEL: 8.15 (+0.01)
Medivation Up 39.6% Since SmarTrend Uptrend Call (MDVN)
Comtex SmarTrend(R) - Mon Jun 27, 12:51PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 3 months, Medivation has returned 39.62% as of today's recent price of $56.61.
MDVN: 62.10 (-0.64)
NIH won't cut price of taxpayer-funded prostate cancer drug
By LINDA A. JOHNSON - AP - Mon Jun 20, 5:25PM CDT
TRENTON, N.J. (AP) — The federal government has declined a petition to lower the price of a drug for advanced prostate cancer developed with taxpayer money.
MDVN: 62.10 (-0.64)
Medivation Up 46.9% Since SmarTrend Uptrend Call (MDVN)
Comtex SmarTrend(R) - Fri Jun 17, 12:47PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 3 months, Medivation has returned 46.92% as of today's recent price of $59.57.
MDVN: 62.10 (-0.64)
Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:56AM CDT
Medivation (MDVN) announced data from a phase I/II study on pidilizumab for the treatment of pediatric with diffuse intrinsic pontine glioma.
MDVN: 62.10 (-0.64), ANIP: 56.51 (-1.61), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
MEDIVATION INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches of Fiduciary Duty
GlobeNewswire - Wed Jun 15, 7:01AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Medivation, Inc. ("Medivation" or the "Company"
.
MDVN: 62.10 (-0.64)
Medivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders
BusinessWire - Mon Jun 13, 7:39AM CDT
--Highlights the Potential of Medivation's Blockbuster XTANDI Franchise and Innovative Late Stage Pipeline to Create Significant Additional Value
MDVN: 62.10 (-0.64)
MEDIVATION (MDVN) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach of Fiduciary Duty
BusinessWire - Mon Jun 13, 7:07AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Medivation, Inc. (NASDAQGS:MDVN) ("Medivation" or the "Company".
MDVN: 62.10 (-0.64)
Medivation Has Returned 48.2% Since SmarTrend Recommendation (MDVN)
Comtex SmarTrend(R) - Fri Jun 10, 12:21AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 3 months, Medivation has returned 48.23% as of today's recent price of $60.10.
MDVN: 62.10 (-0.64)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 62.10 (-0.64), SAN: 3.90 (+0.17), SNY: 40.85 (-0.14)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 62.10 (-0.64), ACAD: 34.62 (+1.11), OPK: 9.87 (+0.01), CLDX: 4.64 (-0.01)
Uptrend Call Working As Medivation Stock Rises 49.5% (MDVN)
Comtex SmarTrend(R) - Thu Jun 02, 12:45PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 2 months, Medivation has returned 49.48% as of today's recent price of $60.61.
MDVN: 62.10 (-0.64)
Medivation and Astellas Initiate Phase III Trial of Enzalutamide in Patients With Triple-Negative Breast Cancer
Marketwired - Thu Jun 02, 6:00AM CDT
SAN FRANCISCO, CA and TOKYO, JAPAN--(Marketwired - June 02, 2016) - Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 62.10 (-0.64)
Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer
PR Newswire - Thu Jun 02, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 62.10 (-0.64)
Medivation Sets Record Date for Sanofi's Proposed Consent Solicitation
BusinessWire - Wed Jun 01, 5:45PM CDT
Medivation, Inc. (NASDAQ:MDVN) today confirmed that it has received a request from Sanofi to establish a record date to determine which of the Company's stockholders are eligible to participate in the proposed solicitation of written consents by Sanofi (the "Sanofi Consent Solicitation". In accordance with that request, the Company's Board of Directors has set the close of business on June 1, 2016 as the record date for the Sanofi Consent Solicitation.
MDVN: 62.10 (-0.64)
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 62.10 (-0.64), SAN: 3.90 (+0.17), SNY: 40.85 (-0.14)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.10 (-0.64), BIIB: 251.30 (+4.03), VRTX: 88.96 (-1.09), GILD: 86.55 (+1.08), UNH: 141.27 (+0.47), MRK: 59.35 (+0.57), ALXN: 124.42 (+1.08), XOM: 93.54 (+0.58), CVX: 104.77 (+1.72), REGN: 378.35 (+6.90), CELG: 105.03 (+0.62)
Blog Coverage Biotech Major Medivation Open to Takeover Talks
ACCESSWIRE - Wed Jul 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / July 6, 2016 / Active Wall St. blog coverage looks at the headline from Medivation Inc. (NASDAQ: MDVN) as the U.S. company signs confidentiality agreements with Paris-based Sanofi S.A. (NYSE: SNY), Pfizer Inc. (NYSE: PFE) and Celgene Corp. (NASDAQ: CELG) among others. Register with us now for your free membership and blog access at:
MDVN: 62.10 (-0.64), PFE: 36.12 (+0.35), ABBV: 64.16 (+0.73), SNY: 40.85 (-0.14), CELG: 105.03 (+0.62)
Medivation Enters into Confidentiality Agreements, Including with Sanofi
BusinessWire - Tue Jul 05, 3:15PM CDT
--Board Committed to Delivering Value and Acting in Stockholders' Best Interests
MDVN: 62.10 (-0.64)
Merger & Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizer's $5.2 Billion Purchase
ACCESSWIRE - Thu Jun 30, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / June 30, 2016 / The Biotech Industry received a boost last month after Pfizer Inc. announced its acquisition of Anacor Pharmaceuticals Inc. and its eczema gel, crisaborole, for $5.2 billion. Under the terms of the deal, Pfizer agreed to pay $99.25 per share in cash for Anacor, which represented a 55 percent premium to Anacor's closing price of $64.03 on May 13th. The transaction has already received approval from both the company's board of directors and is expected to be completed in the third quarter of 2016. The acquisition could potentially kick start merger and acquisition activity within the biotech industry as larger pharmaceutical and biotech companies will also look to boost revenues through acquisitions. Register with us now for your free membership and gain access to our biotech reports at: www.rdinvesting.com. Today we feature reports on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Exelixis, Inc. (NASDAQ: EXEL), Medivation Inc. (NASDAQ: MDVN) and Novavax, Inc. (NASDAQ: NVAX).
MDVN: 62.10 (-0.64), ACAD: 34.62 (+1.11), NVAX: 7.62 (+0.16), PFE: 36.12 (+0.35), ANAC: 99.06 (-0.14), EXEL: 8.15 (+0.01)
Medivation Up 39.6% Since SmarTrend Uptrend Call (MDVN)
Comtex SmarTrend(R) - Mon Jun 27, 12:51PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 3 months, Medivation has returned 39.62% as of today's recent price of $56.61.
MDVN: 62.10 (-0.64)
NIH won't cut price of taxpayer-funded prostate cancer drug
By LINDA A. JOHNSON - AP - Mon Jun 20, 5:25PM CDT
TRENTON, N.J. (AP) — The federal government has declined a petition to lower the price of a drug for advanced prostate cancer developed with taxpayer money.
MDVN: 62.10 (-0.64)
Medivation Up 46.9% Since SmarTrend Uptrend Call (MDVN)
Comtex SmarTrend(R) - Fri Jun 17, 12:47PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 3 months, Medivation has returned 46.92% as of today's recent price of $59.57.
MDVN: 62.10 (-0.64)
Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:56AM CDT
Medivation (MDVN) announced data from a phase I/II study on pidilizumab for the treatment of pediatric with diffuse intrinsic pontine glioma.
MDVN: 62.10 (-0.64), ANIP: 56.51 (-1.61), PFE: 36.12 (+0.35), BMY: 75.28 (+1.20)
MEDIVATION INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches of Fiduciary Duty
GlobeNewswire - Wed Jun 15, 7:01AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Medivation, Inc. ("Medivation" or the "Company"
. MDVN: 62.10 (-0.64)
Medivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders
BusinessWire - Mon Jun 13, 7:39AM CDT
--Highlights the Potential of Medivation's Blockbuster XTANDI Franchise and Innovative Late Stage Pipeline to Create Significant Additional Value
MDVN: 62.10 (-0.64)
MEDIVATION (MDVN) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach of Fiduciary Duty
BusinessWire - Mon Jun 13, 7:07AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Medivation, Inc. (NASDAQGS:MDVN) ("Medivation" or the "Company"
. MDVN: 62.10 (-0.64)
Medivation Has Returned 48.2% Since SmarTrend Recommendation (MDVN)
Comtex SmarTrend(R) - Fri Jun 10, 12:21AM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 3 months, Medivation has returned 48.23% as of today's recent price of $60.10.
MDVN: 62.10 (-0.64)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 62.10 (-0.64), SAN: 3.90 (+0.17), SNY: 40.85 (-0.14)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 62.10 (-0.64), ACAD: 34.62 (+1.11), OPK: 9.87 (+0.01), CLDX: 4.64 (-0.01)
Uptrend Call Working As Medivation Stock Rises 49.5% (MDVN)
Comtex SmarTrend(R) - Thu Jun 02, 12:45PM CDT
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on March 24th, 2016 at $40.54. In approximately 2 months, Medivation has returned 49.48% as of today's recent price of $60.61.
MDVN: 62.10 (-0.64)
Medivation and Astellas Initiate Phase III Trial of Enzalutamide in Patients With Triple-Negative Breast Cancer
Marketwired - Thu Jun 02, 6:00AM CDT
SAN FRANCISCO, CA and TOKYO, JAPAN--(Marketwired - June 02, 2016) - Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 62.10 (-0.64)
Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer
PR Newswire - Thu Jun 02, 6:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment of triple-negative breast cancer (TNBC). The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative BReast Cancer) trial will evaluate the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic TNBC whose tumors test positive for a novel gene expression profile, which is referred to as diagnostic-positive TNBC. The trial, which will be led by Medivation, is expected to begin patient enrollment in the fourth quarter of 2016.
MDVN: 62.10 (-0.64)
Medivation Sets Record Date for Sanofi's Proposed Consent Solicitation
BusinessWire - Wed Jun 01, 5:45PM CDT
Medivation, Inc. (NASDAQ:MDVN) today confirmed that it has received a request from Sanofi to establish a record date to determine which of the Company's stockholders are eligible to participate in the proposed solicitation of written consents by Sanofi (the "Sanofi Consent Solicitation"
. In accordance with that request, the Company's Board of Directors has set the close of business on June 1, 2016 as the record date for the Sanofi Consent Solicitation. MDVN: 62.10 (-0.64)
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 62.10 (-0.64), SAN: 3.90 (+0.17), SNY: 40.85 (-0.14)
